Press Releases June 29, 2026 07:00 AM

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

Agios Pharmaceuticals announces date for Q2 2026 financial results conference call and webcast

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
AGIO

Agios Pharmaceuticals, a commercial-stage biopharmaceutical company specializing in rare diseases, will hold a conference call and webcast on July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The event will be accessible via the company's investor website, with a replay available afterward.

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
AGIO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Agios focuses on innovative medicines targeting rare diseases, particularly in hematology.
  • The company is holding its Q2 2026 earnings call and webcast on July 30, providing an update on financials and business progress.
  • Agios emphasizes transparent investor communications through multiple channels, including webcasts and SEC filings.

CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios
To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
[email protected]

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
[email protected]


Risks

  • As a biopharmaceutical company in the rare disease sector, Agios faces clinical and regulatory risks impacting drug development and approval.
  • Market performance may be influenced by competitive pressures within the biotech and pharmaceutical industries.
  • Uncertainty exists around upcoming financial results which could impact investor sentiment and stock volatility.

More from Press Releases

EMPLOYERS Appoints Jeffrey P. Lisenby as Executive Vice President, General Counsel Jun 29, 2026 Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government Jun 29, 2026 SailPoint completes acquisition of Entro Security to secure agentic identities Jun 29, 2026 Creative Realities Announces Pricing of $12 Million Public Offering Jun 29, 2026 Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression Jun 29, 2026